source
- Elevar Therapeutics receives FDA approval for Lyrfigtu as second-line treatment for bile duct cancerThe U.S. Food and Drug Administration has approved Elevar Therapeutics' drug Lyrfigtu as a second‑line option for patients with bile duct cancer who meet specific criteria. Bile duct cancer is dia…
- FDA nominee Heidi Overton affirms safety of vaccines and mifepristone in Senate hearingHeidi Overton, the Trump administration’s pick for FDA commissioner, appeared before the Senate Health, Education, Labor and Pensions Committee to answer questions about her views on key public‑hea…